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Abstract
Background: To explore the current models of practice in centres delivering specialist care for children with
disorders of sex development (DSD), an international survey of 124 clinicians, identified through DSDnet and
the I-DSD Registry, was performed in the last quarter of 2014.
Results: A total of 78 (63 %) clinicians, in 75 centres, from 38 countries responded to the survey. A formal
national network for managing DSD was reported to exist in 12 (32 %) countries. The paediatric specialists
routinely involved in the initial evaluation of a newborn included: endocrinologist (99 %), surgeon/urologist
(95 %), radiologist (93 %), neonatologist (91 %), clinical geneticist (81 %) and clinical psychologist (69 %).
A team consisting of paediatric specialists in endocrinology, surgery/urology, clinical psychology, and nursing
was only possible in 31 (41 %) centres. Of the 75 centres, 26 (35 %) kept only a local DSD registry and 40
(53 %) shared their data in a multicentre DSD registry. Attendance in local, national and international DSD-
related educational programs was reported by 69, 78 and 84 % clinicians, respectively. Participation in audits/quality
improvement exercises in DSD care was reported by 14 (19 %) centres. In addition to complex biochemistry and
molecular genetic investigations, 40 clinicians (51 %) also had access to next generation sequencing. A genetic test
was reported to be more preferable than biochemical tests for diagnosing 5-alpha reductase deficiency and 17-beta
hydroxysteroid dehydrogenase 3 deficiency by 50 and 55 % clinicians, respectively.
Conclusion: DSD centres report a high level of interaction at an international level, have access to specialist staff and
are increasingly relying on molecular genetics for routine diagnostics. The quality of care provided by these centres
locally requires further exploration.
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Background
Disorders of sex development (DSD) encompass a var-
iety of different rare conditions that share a discordance
in the typical chromosomal, gonadal and/or phenotypic
sex. The consensus, reached in 2005, on the general
principles of managing people with DSD represented a
historic milestone for international and multidisciplinary
collaboration in this area [1]. This consensus coincided
with an increased global emphasis on the development
of centres of expertise for rare conditions [2, 3]. Funding
by an EU Seventh Framework Programme and a UK
Medical Research Council grant supported the develop-
ment of the International DSD Registry (I-DSD). This
Registry has users from 50 countries from all 6 habitable
continents. Of these countries, there are 59 centres that
have entered almost 2500 cases [4]. More recently, the
European Cooperation of Science and Technology
(COST) Action DSDnet [5] supported the development
of a network of clinicians, scientists and the affected
community. Currently, 23 European countries have
joined and, in partnership with 3 near neighbour and 5
international countries, are aiming to create a network
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to provide general information on DSD, and to give ac-
cess to national specialist centres. It is anticipated that
rare disease registries and forthcoming development of
formal clinical and research networks will help establish
a clinical framework for all centres of expertise by defin-
ing a standard of care as well as setting future research
priorities in DSD [3].
A fundamental recommendation of the 2005 state-
ment was that of a multidisciplinary team (MDT)
approach to management of DSD, representing the
new standard of care and support for children and
their families [1, 6]. As a minimum standard, the spe-
cialist clinical MDT should include specialists in
endocrinology, surgery and/or urology, clinical psych-
ology/psychiatry, radiology, and nursing. In addition
to delivery of clinical care, the MDT would have a
responsibility to both educate healthcare staff outwith
the MDT and to maintain the professional develop-
ment of its own members through educational, audit
and research activities [6].
The approach to investigating a newborn with a sus-
pected DSD is likely to vary between centres and may be
influenced by local availability and technological devel-
opments. Advances in biochemical analytical methods
have led to an increase in the specificity and accuracy of
measurement of steroid hormones and their metabolites
in plasma and urine in the diagnostic work up of DSD
[7–9]. Simultaneous developments in genetic and gen-
omic technologies, combined with a marked reduction
in costs, has provided a stimulus for change, with next-
generation sequencing and whole-genome and -exome
sequencing opening novel diagnostic strategies and
expanding our knowledge of the underlying mechanisms
of DSD [10].
With the advent of increasing international networks
for rare conditions such as DSD, and the recent
advances in diagnostics, there is a need to establish how
closely specialist centres meet proposed standards in-
cluding access to members of an MDT and local avail-
ability of desirable investigations. The aim of the study
was to define the current models of multidisciplinary
practice and to explore the diagnostic approach of clini-
cians delivering specialist care for children with DSD.
Methods
Design of survey
A working group of DSDnet conducted an international
survey of centres/clinicians delivering specialist care for
DSD. The working group consisted of professionals from
paediatric endocrinology (AK, AJ, VI, OH, SFA), clinical
psychology (AD), support group (MR), clinical genetics
(MK), paediatric urology (AN), specialist nursing (CS)
and project manager (JB). A preliminary version of the
survey was piloted on clinicians of different clinical
background and nationality to assess readability and
time required for completion. The draft questionnaire
was sent for review to all the members of the manage-
ment committee of DSDnet. The final draft was
reviewed and approved by all the group members. The
duration of the survey was for two months between
October 2014 and December 2014 and 124 clinicians
working in the field of paediatric endocrinology, identi-
fied through the DSDnet management committee (web-
site) as well as the registered clinical users of the I-DSD
registry, were invited to participate (Table 1).
The survey contained 17 items/questions divided into
2 sections. Items in the first section, directed to
responding centres, included assessing MDT organisa-
tion and collaboration, networking, participation in
clinical audit or quality improvement exercises, dissem-
ination of knowledge, professional development, and the
use of databases and data sharing. In the second section,
directed to individual responding clinicians, participants
were presented with the following clinical scenario: a
newborn with palpable gonads in the upper inguinal
region and genitalia that are so unusual in appearance
that sex cannot be assigned at birth. The surveyed clini-
cians were then asked about their diagnostic approach,
including specific details of the biochemical and genetic
investigations they would perform in such circumstances
and whether these tests were available locally in accre-
dited clinical laboratories.
Table 1 The response rate to the questionnaire in each region per clinician, centre and country
Sent Responses
Region Clinicians Centres Countries Clinicians Centres Countries
n n n n % n % n %
Europe 85 77 21 47 55 45 58 17 81
North America 7 7 2 5 71 5 71 2 100
South America 5 5 3 4 80 4 80 3 100
Africa 7 6 5 6 86 5 83 5 100
Asia & Australia 20 20 11 16 80 16 80 11 100
Total 124 115 42 78 63 75 65 38 91
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Analyses were conducted using IBM SPSS version 22
(SPSS Inc, Chicago). Variables are expressed as the value
(percentage frequency). Comparison between groups, in
which diagnostic and genetic tests are available or
unavailable in a local accredited laboratory, was per-
formed by χ2 test or Fisher’s exact test. All tests were
two-sided and P <0.05 was considered significant.
Results
Response rate and participants
A total of 124 clinicians from 115 centres in 42 coun-
tries were sent the questionnaire and the response rate
to the questionnaire for clinician, centre and region is
presented in Table 1. A total of 78 (63 %) clinicians from
75 (67 %) centres in 38 (91 %) countries responded to
the survey. The respondent’s professional role was
reported as paediatric endocrinologist in 70 (90 %),
clinical geneticist in 4 (5 %), paediatrician in 2 (3 %),
neonatologist in 1 (1 %) and adult endocrinologist in 1
(1 %). Of the 78 respondents, 68 (87 %) identified them-
selves as the clinical lead of the team that provided the
clinical service for DSD in their centre.
Formal national networks
A nationally organised formal network or a national
plan for managing DSD was reported to exist in 12
(32 %) of the 38 countries. These countries were:
Belgium (Belgisch Plan voor Zeldzame ziekten,
Belgian-Luxembourg DSD network and registry),
Brazil (DDSBrasil), Bulgaria (National Alliance of
People with Rare Diseases), Finland (Finnish Research
Network on Disorders of Sex Development), France
(Centre de Référence Médico-Chirurgical des Maladies
Rares du Développement et de la Différenciaton
Sexuel), Germany (National Action Plan for Rare
Diseases), Indonesia (Team Penyesuaian Kelamin/
Sexual Adjustment team), Japan (DSD committee of
Japanese Society for Pediatric Endocrinology), Kuwait
(Kuwait DSD network), Spain (Working Group on
DSD of the Spanish Society for Paediatric Endocrin-
ology), Sweden (Sveriges Nationella Nätverk för DSD)
and Scotland within the UK (the Scottish DSD
network).
MDT organisation and collaboration
In 62 (83 %) of the 75 centres, the clinical lead of the
MDT that provided DSD care was reported as a paediat-
ric endocrinologist. The next commonest clinical lead
was a clinical geneticist in 5 (7 %) centres. The paediat-
ric specialists involved in the initial evaluation of a new-
born with suspected DSD in the 75 centres are shown in
Fig. 1. During the first week after presentation, a joint
MDT assessment comprising paediatric specialists in
endocrinology, surgery/urology, clinical psychology, and
nursing, available in the same centre or as a part of a
regional network, was possible in 31 (41 %) of the 75
centres. In the subsequent follow-up, over the first three
months after the presentation of a newborn with
suspected DSD, the paediatric specialists involved in the
75 centres are shown in Fig. 2. A team comprising of
paediatric specialists in endocrinology, surgery/urology,
clinical psychology, nursing and clinical genetics, avail-
able in the same centre or as a part of a regional
network, was possible in 32 (43 %) centres. A paediatric
specialist nurse was the commonest missing specialist
from the MDT and was reported as desirable but not
available in 22 (29 %) centres during initial evaluation
and in 22 (29 %) centres during the following three
months, while it was reported as not necessary in 14
(19 %) centres during the initial evaluation and in 13
(17 %) centres during the subsequent follow-up.
Similarly, a clinical psychologist was desirable but not
available in 18 (24 %) centres during initial evaluation
and in 14 (19 %) centres during the next three months,
while this requirement was reported as not necessary in
5 (7 %) centres during the initial evaluation and in 2
(3 %) centres during the subsequent follow-up. Links to
a wider MDT consisting of specialists from adult endo-
crinology, gynaecology, biochemistry, social work and, to
a clinical ethics forum was only possible in 6 (8 %) cen-
tres. Notably, 46 (61 %) centres reported the presence of
a peer support group as desirable but not available in
their region.
Participation in registries, audits and quality
improvement exercises
Of the 75 centres, 26 (35 %) reported that they only kept
a local DSD registry, 40 (53 %) share their data in a mul-
ticentre, national or the International DSD registry and
9 centres (12 %) did not record any data. The main hur-
dles for participation in a registry were reported as lack
of personnel by 48 centres (64 %), lack of available time
by 42 centres (56 %) and difficulties in obtaining consent
by 20 (27 %). Of the 75 centres, 14 (19 %) from 6 (16 %)
countries reported that they participated in audit or
quality improvement exercises in the field of DSD care.
Professional development in DSD care
Of the 75 centres, 60 (80 %) were involved in organising
meetings and case discussions, 42 (56 %) in involving
students in research projects and 41 (55 %) in organising
training days. Additional methods for disseminating
knowledge in DSD included the invitation of health care
professionals to participate in DSD clinics (26 centres,
35 %) and use of e-learning tools (13 centres, 17 %). Ten
centres (13 %) reported no educational activities for
engaging other health professionals. Of the 78 respond-
ing clinicians, 54 (69 %) had attended a local education
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event related to DSD within the year prior to the survey,
the corresponding figures for attending a national or
international event were 61 (78 %) and 64 (84 %),
respectively. Of the 78 clinicians, 10 (13 %) attended
only international educational programs and only 4
(5 %) did not attend any meeting.
Selection & availability of endocrine & cytogenetic
diagnostic tests
The investigations that clinicians would perform, at ini-
tial and subsequent follow-up, in a suspected case of
46,XY DSD are presented in Fig. 3. Of the 78
respondents, the commonest investigations that would
be performed routinely, within the first week of presen-
tation, included testosterone in 76 (97 %), karyotype in
74 (96 %), ultrasound of pelvis and abdomen in 73
(94 %), 17-hydroxyprogesterone in 65 (83 %), andro-
stenedione in 58 (75 %), dihydrotestosterone (DHT) in
56 (73 %), cortisol in 53 (69 %), X and Y probes by fluor-
escence in situ hybridization (FISH) or polymerase chain
reaction (PCR) in 53 (69 %) and anti-Müllerian hormone
(AMH) in 45 (58 %).
We compared the selection of a diagnostic test on the
basis of access to a locally accredited laboratory. A
Fig. 1 Individual paediatric specialist involvement in the initial evaluation of a newborn with suspected DSD in the 75 centres surveyed
Fig. 2 Individual paediatric specialist involvement during the first three months after presentation of a newborn with suspected DSD in the 75
centres surveyed
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diagnostic test was reported to be available, in a locally
accredited laboratory, when all tests were considered, in
85 % of the cases. In 60 % of those cases, with access to
an accredited laboratory, the clinicians reported that
they would select that test routinely and in 4 % the test
would never be selected. In the 15 % of the cases, with
no local accredited laboratory, only 30 % of the tests
would be selected routinely and in 15 % the test would
never be selected (p < 0.0001).
The most commonly unavailable diagnostic tests were
urine steroid profile (n, 41, 53 %), array Comparative
Genomic Hybridisation (CGH) (n, 21, 27 %), AMH (n,
16, 21 %) and DHT (n, 15, 19 %). When access to urine
steroid profile was not available, 33 of 41 (81 %)
clinicians would consider performing this test, if the
test was available. The corresponding figures were 14
(67 %) for array CGH,16 (100 %) for AMH and 15
(100 %) for DHT.
Selection & availability of molecular genetic tests
A majority of clinicians surveyed had access to a panel
of genes commonly affected in XY DSD, however, in a
large proportion this access was only available in
research laboratories and not in clinically accredited
laboratories (Fig. 4). Of the 78 clinicians, 62 (80 %)
would perform routinely at least one genetic test (Fig. 5).
The most common genetic tests that clinicians would
perform routinely in a case of 46,XY DSD included SRY
in 40 (51 %), AR in 33 (43 %), SRD5A2 in 24 (31 %) and
NR5A1 in 20 (26 %). It was also noted that 14 (18 %)
and 10 (13 %) would routinely consider performing a
wider panel of genes and exomic/genomic analysis
respectively. In addition, if family history and/or bio-
chemistry were suggestive, clinicians would check DAX1
in 57 (73 %), WT1 in 56 (71 %), NR5A1 in 51 (65 %),
SRD5A2 in 49 (62 %) and SOX9 in 48 (61 %).
Conversely, 24 (31 %) clinicians reported that they
would never perform exomic/genomic analysis and 24
(31 %) would never perform a wider panel of genes in
reference to the same case of 46,XY DSD.
We compared the selection of a genetic test on the
basis of access to a locally accredited laboratory. Overall,
clinicians reported access to a genetic test in a local
accredited laboratory in 38 %. Presented with a case of a
newborn with 46,XY DSD and a locally available genetic
test in an accredited laboratory, in 95 % of the cases the
clinicians would select this test as matter of routine or if
family history and/or biochemistry were suggestive of a
diagnosis. Clinicians reported a lack of local availability
to a genetic test in 62 % of cases and, in 22 % of these
Fig. 3 Selection preference for biochemical, cytogenetic, and imaging diagnostic tests of the 78 clinicians surveyed, at initial and subsequent
follow-up, in a suspected case of 46,XY DSD. hCG, human chorionic gonadotropin; array CGH, array comparative genomic hybridisation; FISH,
fluorescence in situ hybridisation; PCR, polymerase chain reaction
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cases the clinicians would never consider performing
this test (p < 0.0001).
Condition specific preference of investigations in 46,XY
DSD
The surveyed clinicians were asked to choose be-
tween molecular genetic and biochemical confirm-
ation for diagnosing a case of 5α reductase deficiency
and a case of 17β hydroxysteroid dehydrogenase 3
(17βHSD3) deficiency. For 5α reductase deficiency,
39 (50 %) clinicians selected genetic testing; 29
(37 %) selected testosterone: DHT ratio; and 10
(13 %) selected urine steroid profile as the single
most preferable test in diagnosis. For diagnosing
17βHSD3 deficiency, 43 (55 %) clinicians selected
genetic testing; 25 (32 %) selected testosterone: DHT
ratio; and 10 (13 %) selected urine steroid profile as
the single most useful test in diagnosis.
Fig. 5 Selection preference for molecular genetic tests of the 78 clinicians surveyed, in the case of a newborn infant with 46,XY DSD
Fig. 4 Local availability of individual genetic tests, either in accredited laboratories or as part of a research study, of 78 clinicians surveyed, both
frequency and percentage
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Discussion
The aim of this study was to explore the current models
of care of clinicians working in specialist centres for
DSD. The response rate to the survey was good, and the
respondents represented centres from all continents and
with different financial and cultural backgrounds.
Our study showed that the majority of centres imple-
mented an MDT, allowing the possibility for families to
be supported and make informed decisions at a crucial
time. A previous study of 60 DSD centres in 23 coun-
tries, reported close to full cover, in 58 % of centres,
from those subspecialties recommended by the 2005
Consensus [1], whilst only 7 % of centres were missing a
key service, that is, paediatric endocrinologist, urologist/
surgeon and/or psychological services, suggesting that
the multidisciplinary approach to DSD had been suc-
cessfully implemented across Europe [11]. A major dif-
ference from our study was that the previous study
asked about the presence of specialists involved at any
stage of the child’s clinical journey and not specifically at
the time of initial approach or proceeding three months.
Our study showed that only 40 % of the centres had an
MDT inclusive of paediatric specialists in endocrinology,
surgery/urology, clinical psychology, and nursing avail-
able during the initial approach, and only 40 % had a
joint team consisting of paediatric specialists in endo-
crinology, surgery/urology, clinical psychology, nursing
and clinical genetics during the proceeding three
months. Most commonly, a specialist nurse and psych-
ologist were missing from the MDT, and conversely the
majority of clinicians reported that they would wish in-
volvement of a nurse or psychologist in those circum-
stances where they were unavailable. It can be inferred
that the majority of clinicians understand the import-
ance of all denoted key members of the MDT, and with-
out imposed financial constraints would wish to design a
service that had capacity to offer the benefits of holistic
care to any given family [12].
The 2005 Consensus and, more recently, the EU cri-
teria for centres of expertise, have highlighted the need
for the creation and maintenance of a database for rare
conditions such as DSD [2, 13]. Such databases exist in
many regional and national centres, as 90 % of the
centres in this study reported keeping a DSD database,
and to date have provided invaluable insight into several
aspects of DSD including epidemiology [14, 15],
aetiology [16], disease expression [17] and long-term
outcome [18, 19]. In this study, half of the centres re-
ported sharing their data in a multicentre registry. It is
possible that the true participation in such registries is
much lower as clinicians invited to complete the survey
were in part identified through the I-DSD registry. The
reported barriers to using a registry included time and
personnel support and these are areas that will need to
be addressed. Whilst consent was reported as another bar-
rier, preliminary data from a survey of service users in one
centre did not raise this as an important issue [20].
Most centres surveyed reported a lack of participation
in formal clinical audit. Assessing outcome, patient satis-
faction and quality of care provided, i.e. not only an
expression of which specialists and at what time, is
inherently more difficult, and requires participation in
internal and external quality schemes which may in turn
produce quality of care indicators and implement out-
come measures [2, 21, 22]. It is possible that some cen-
tres may have been involved in audit activities targeted
at laboratory processes but these were not captured. To
maintain expertise of rare diseases, clinicians should
engage in continuous professional development through
attendance at specialist meetings and discussion of com-
plex cases with international colleagues. Presently, main-
tenance of an individual clinician’s educational needs
often requires attendance at international conferences.
This study confirmed that local access to specialist
biochemical and genetic tests influences the diagnostic
process. It has been shown previously that in many
Western European countries, such as UK, Germany and
France, the use of national networks allowed for timely
provision of almost all biochemical and genetic tests,
while in other countries, many tests are performed in
private laboratories or through international collabor-
ation, with long turnaround times [23]. The rationale for
investigating a newborn with a suspected DSD may in-
clude the need to determine the sex of rearing, to antici-
pate early medical problems, to explain the aetiology of
DSD and to develop a long-term management plan. The
current initial approach of most surveyed clinicians is to
utilise those investigations which offer additional pheno-
typic information, and would include urgent endocrine
testing (testosterone, 17-hydroxyprogesterone, cortisol)
imaging studies (pelvic ultrasound), and rapid identifica-
tion of the sex chromosome complement by karyotype
analysis or FISH/PCR with X and Y probes. In those
cases where investigations were not available locally,
commonly urine steroid profiles, AMH or array CGH,
there was greater disparity in whether these investiga-
tions were offered as first or second line.
Molecular genetic testing, either of single candidate
genes or a gene panel, is increasingly common in spe-
cialist centres, as approximately 80 % of clinicians would
perform genetic testing as routine in a newborn with
suspected 46,XY DSD and 50 % of them would select
genetic testing as the single most preferable method for
diagnosis. As new genomic technologies have rapidly be-
come an integral part of the diagnostic armoury in the
field of DSD, a suggested alternative diagnostic approach
would make use of next generation sequencing (NGS) as
first-line [10, 24]. Notably, nearly one-fifth of the
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surveyed clinicians reported ready availability and prefer-
ence to this approach. However, this approach may face
hurdles including long turnaround times, high costs, and
difficulties in the interpretation of the results. These ob-
stacles are likely to be overcome in the future, and NGS
is likely to become the mainstay of investigations in
diagnosis of DSD. Although, the majority of the respon-
dents to this survey suggested that genetic testing should
be targeted and based on history and biochemical char-
acteristics, it was interesting to note that the majority of
respondents believed that a genetic confirmation of a
diagnosis was preferable to a biochemical confirmation
when encountering a case of 5α reductase deficiency or
17βHSD3 deficiency, highlighting the shift towards mo-
lecular genetics and an appreciation of the lack of sensi-
tivity in arbitrary metabolite ratios in diagnosing these
conditions [25–27].
Differences in the composition of the MDT as well
as diagnostic tests have been highlighted by others
[23] and will be influenced by local medical, financial,
geographic, or personal reasons. A model for delivery
of education should be analogous to that of clinical
support offered to local centres. In the best examples
provided, regional centres are responsible for dissem-
inating knowledge to local centres through opportun-
ities for clinical meetings, case discussion and
observation in regional DSD clinics; organising con-
ferences and training days accessible to all health care
professionals; and use of e-learning tools. Whilst a
number of centres were involved in continuous pro-
fessional development, there is clearly a need to ex-
plore other models. Unlike clinical support, it is
possible that the use of remote technology may lead
to wider involvement in educational events.
Approximately one third of countries or regions sur-
veyed, had attempted to overcome these hurdles with
the development of managed clinical networks for rare
conditions such as DSD. The remit of a clinical network
should be to ensure the provision of an equitable state
of-the-art service for all affected children and adoles-
cents in a region through formal structured referral
pathways. A network also facilitates the creation of pro-
tocols, with consideration for local and national avail-
ability of services, setting and monitoring of national
standards of care, rational utilisation of other services
such as clinical genetics and clinical biochemistry and
provides a forum for education and professional devel-
opment. Research and audit are vital for the manage-
ment of DSD, and clinical networks have a strong
potential to drive these activities with the development
of care standards including patient experience data and
peer-observation of clinical care provision [6, 28–30]. In
cases where there is uncertainty at a regional level, there
is a need to create a worldwide network of experts and
stakeholders in DSD, linking existing national and re-
gional networks throughout the world.
There are limitations inherent in a questionnaire-
based study due to the nature of data collection and
potential response bias. Thirty-seven percent of clini-
cians invited to participate did not respond to the survey
and, therefore, it is possible that response rates were
higher among centres with practices more compliant
with the proposed standards of care and would effect-
ively produce a positive bias in our report. Gathering
more detailed information on each centre may have been
advantageous if we wished to further delineate those
factors, which were associated with response, but a
balance needed to be struck between maximising data
collection and achieving a desirable response rate. Over-
all, there was international participation to the survey,
however some countries were relatively over-represented
(UK, Germany, Bulgaria, Spain, Turkey) and participating
centres within countries did not provide uniform coverage
to all geographical areas. It is possible that practice and in-
stitutional characteristics vary between regions and coun-
tries, factors which may influence results of the study.
Conclusion
In summary, we report the findings of a large, inter-
national survey of DSD specialist centres, reflecting con-
temporary clinical practice in DSD. An increasing number
of DSD centres have access to specialist staff, however a
gap still exists between the current models of clinical care
and that of the ideal comprehensive MDT. We have fo-
cussed here on the clinical infrastructure, however the ac-
tual delivery and quality of care provided in the MDT
described requires further exploration through both clin-
ical audit and individual user feedback. We have shown a
considerable variation in the diagnostic evaluation of a
newborn with suspected DSD, an apparent shift towards
molecular genetic testing, and have provided evidence that
access to specialist tests influences the diagnostic process.
Collaboration through a network of specialist centres
could assist in bridging gaps in access to expert clinicians
and other key members of the MDT and diagnostic inves-
tigations for DSD. With the emergence of a new era of
medical management that demands collaborative and
whole-systems treatment for these complex conditions,
the medical community in partnership with individuals
with DSD, families and support groups has a unique
opportunity to move to the next phase of developing
measurable standards of DSD care.
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